CoChat

Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial

Open access

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background: Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States. and globally. Using pooled efficacy data from six phase 2 trials, therapy using 3,4-methylenedioxymethamphetamine (MDMA) appeared cost-saving from a payer’s perspective. This study updates the cost-effectiveness analysis of this novel therapy using data from a new phase 3 trial, including the incremental cost-effectiveness of the more intensive phase 3 regimen compared with the shorter phase 2 regimen. Methods: We adapted a previously-published Markov model to portray the costs and health benefits of providing MDMA-assisted therapy (MDMA-AT) to patients with chronic, severe, or extreme PTSD in a recent phase 3 trial, compared with standard care. Inputs were based on trial results and published literature. The trial treated 90 patients with a clinician administered PTSD scale (CAPS-5) total severity score of 35 or greater at baseline, and duration of PTSD symptoms of 6 months or longer. The primary outcome was assessed 8 weeks after the final experimental session. Patients received three 90-minute preparatory psychotherapy sessions, three 8-hour active MDMA or placebo sessions, and nine 90-minute integrative psychotherapy sessions. Our model calculates the per-patient cost of MDMA-AT, net all-cause medical costs, mortality, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). We reported results from the U.S. health care payer’s perspective for multiple analytic time horizons, (base-case is 30 years), and conducted extensive sensitivity analyses. Costs and QALYs were discounted by 3% annually. Costs were adjusted to 2020 U.S. dollars according to the medical component of the U.S. Bureau of Labor Statistics’ Consumer Price Index (CPI). Results: MDMA-AT as conducted in the phase 3 trial costs $11,537 per patient. Compared to standard of care for 1,000 patients, MDMA-AT generates discounted net health care savings of $132.9 million over 30 years, accruing 4,856 QALYs, and averting 61.4 premature deaths. MDMA-AT breaks even on cost at 3.8 years while delivering 887 QALYs. A third MDMA session generates additional medical savings and health benefits compared with a two-session regimen. Hypothetically assuming no savings in health care costs, MDMA-AT has an ICER of $2,384 per QALY gained. Conclusions: MDMA-AT provided to patients with severe or extreme chronic PTSD is cost-saving from a payer’s perspective, while delivering substantial clinical benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0263252

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 MDMA-assisted therapy costs by component; Total: $11,537 per patient.
Fig 1 MDMA-assisted therapy costs by component; Total: $11,537 per patient.CC BY · PubMed Central
Fig 2 One-way sensitivity analyses. Net cost (neg = savings) of MDMA-AT over 30-year analytic time horizon; for 1,000 patients using input variables across the range of values shown in Table 1; Inputs ranked by effect on output mean.
Fig 2 One-way sensitivity analyses. Net cost (neg = savings) of MDMA-AT over 30-year analytic time horizon; for 1,000 patients using input variables across the range of values shown in Table 1; Inputs ranked by effect on output mean.CC BY · PubMed Central
Fig 3 Multivariable sensitivity analysis on net cost (neg. = savings). 10,000 iterations of a Monte Carlo simulation assuming PTSD progression risk varied from 0.05 to 0.15 annually in a uniform distribution in patients receiving MDMA-AT; 1,000 patients over a 30-year analytic horizon.
Fig 3 Multivariable sensitivity analysis on net cost (neg. = savings). 10,000 iterations of a Monte Carlo simulation assuming PTSD progression risk varied from 0.05 to 0.15 annually in a uniform distribution in patients receiving MDMA-AT; 1,000 patients over a 30-year analytic horizon.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 50

Metadata

Authors
Marseille, E., Mitchell, J. M., & Kahn, J. G.
Affiliations
  • University of California, Berkeley (US)
  • University of California, San Francisco (US)
Corresponding author
Marseille, Elliot
Venue
PLOS ONE
Published
2022-02-25
Volume
17
Issue
2
Pages
e0263252
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4214531716
Cited by
50
References
18
Citations by year
2026: 7 · 2025: 15 · 2024: 8 · 2023: 16 · 2022: 4
FWCI
8.65
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Global Brain Health Institute
  • Trinity College Dublin
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
Keywords
MDMA-assisted psychotherapy, MDMA, post-traumatic stress disorder, cost-effectiveness, Markov model, quality-adjusted life years, incremental cost-effectiveness ratio, treatment duration, health care costs, quality of life, payer perspective, integrative psychotherapy, medical cost savings, premature mortality, sensitivity analysis, United States health care system, consumer price index
MeSH terms
Adaptation, Physiological, Adult, Cost-Benefit Analysis, Female, Humans, Male, Markov Chains, Psychiatric Status Rating Scales, Stress Disorders, Post-Traumatic, United States, Treatment Outcome, Clinical Trials, Phase III as Topic, N-Methyl-3,4-methylenedioxyamphetamine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.